Chinese anti-tumor drug APG-115 is approved to enter US clinical use

Designed and developed by enterprises with a global intellectual property rights and functioning on the new target MDM2-p53, anticancer drug APG-115 of precision was approved to enter into the US clinic. The project is the fifth product that has entered the clinic of Ascentage Pharma products in the pipeline, and it is also the company's second product that has entered the US clinical-stage.

APG-115 is a small molecule inhibitor which is orally active with highly-selective targeting MDM2-p53 protein bindings. Preclinical data suggest that APG-115 can form a highly efficient suppression to sarcoma, primary liver cancer, primary gastric tumors, and animals test administration can allow tumor to disappear completely. Another study showed that APG-115 has a significant therapeutic effect on dry senile macular disease. Later, Ascentage Pharma will accelerate the progress of APG-115 clinical research for the early project into the market, providing more efficient and safe new treatments for clinical cancer and dry senile macular lesions.

Here is some introduction of Ascentage Pharma. Ascentage Pharma is a clinical-stage biopharmaceutical research and development company based in Chinese medicine and globally oriented. Ascentage Pharma mainly aims at international novel small molecule anticancer drugs targeted development and research and development trends to design, optimize and develop a series of original small molecule targeted anticancer drugs with global proprietary for the treatment of cancer, hepatitis B and anti-diseases of aging. It fills the domestic market of such technology research and product gaps and enters the international market of high-end medicine. Ascentage Pharma has developed a number of core technologies based on drug design and optimization areas targeting protein structure and has nearly dozens of international patents. Cusabio is also a biocompany which is engaged the development production of high-level recombinant human proteins. Up to now, there are five Ascentage Pharma products entered into the United States, Australia and Chinese clinical stage I-II stage. It has been focused on clinically validated cancer targets, and its main R & D product critical path pipeline apoptosis inhibitors of protein restart tumor cells apoptotic program by inhibiting IAP, Bcl-2 / Bcl-xL and MDM2-p53 and so on; the second and third generation inhibitor for the treatment of cancer appears kinase mutation body.